EN
The aim of EPISTOP was to better understand the pathophysiology of epilepsy and its consequences, to develop a preventative strategy for epilepsy, to identify new biomarkers of epilepsy, and to develop new therapeutic targets to block or otherwise modify epileptogenesis in humans. This aim was achieved by a multidisciplinary, systematic approach. First, a prospective study of epilepsy development was conducted in infants with tuberus sclerosis complex (TSC), using a wide range of clinical, neuroimaging, and genetic analyses, including a diverse set of cutting edge analyses of blood samples, at the onset of epileptiform discharges on EEG, at seizure onset and at the age of 24 month. Second, we performed an analysis of biomarkers of epileptogenesis and drug-resistant epilepsy in epileptogenic brain specimens obtained from patients with TSC who underwent epilepsy surgery and TSC autopsy cases collected in the past.